Advances in research on 3C-like protease (3CLpro) inhibitors against SARS-CoV-2 since 2020
Citations Over TimeTop 10% of 2022 papers
Abstract
COVID-19 caused by SARS-CoV-2 in late 2019 is still threatening global human health. Although some vaccines and drugs are available in the market, controlling the spread of the SARS-CoV-2 virus remains a huge challenge. 3C-like protease (3CLpro) is a highly conserved key protease for SARS-CoV-2 replication, and no relevant homologous protein with a similar cleavage site to 3CLpro has been identified in humans, highlighting that development of 3CLpro inhibitors exhibits great promise for treatment of COVID-19. In this review, the authors describe the structure and function of 3CLpro. To better understand the characteristics of SARS-CoV-2 3CLpro inhibitors, the SARS-CoV-2 3CLpro inhibitors reported since 2020 are classified into peptidomimetic covalent inhibitors, non-peptidomimetic covalent inhibitors and non-covalent small molecule inhibitors, and the representative inhibitors, their biological activities and binding models are highlighted. Collectively, we hope that all the information presented here will provide new insights into the design and development of more effective 3CLpro inhibitors against SARS-CoV-2 as novel anti-coronavirus drugs.
Related Papers
- → Long COVID: which symptoms can be attributed to SARS-CoV-2 infection?(2022)33 cited
- → Review of infective dose, routes of transmission and outcome of COVID-19 caused by the SARS-COV-2: comparison with other respiratory viruses– CORRIGENDUM(2021)32 cited
- → Detection of SARS-CoV-2 through pool testing for COVID-19: an integrative review(2021)7 cited
- → ВПЛИВ СТАНУ РОТОВОЇ ПОРОЖНИНИ НА ПЕРЕБІГ ІНФЕКЦІЇ SARS-COV-2(2021)
- → Положительный результат SARS-CoV-2 у плода и пути передачи от матери ребенку: литературный обзор(2022)